HIPEC и PIPAC при раке желудка: методика и сравнение эффективности. Обзор литературы

HIPEC и PIPAC при раке желудка: методика и сравнение эффективности. Обзор литературы

Автор: Осминин С.В., Ветшев Ф.П., Пхакадзе Л.М., Раджабова Г.А., Салпагарова А.И.

Журнал: Злокачественные опухоли @malignanttumors

Рубрика: Собственные исследования

Статья в выпуске: 4 т.13, 2023 года.

Бесплатный доступ

Актуальность: По данным Всемирной Организации Здравоохранения (ВОЗ) в 2020 году рак желудка (РЖ) занимал 5‑е место по частоте встречаемости и 4‑е по частоте смертности в мире среди онкологических заболеваний. Перитонеальные метастазы (ПМ) выявляют у 30% больных местнораспространенным РЖ, а медиана общей выживаемости у пациентов с ПМ составляет 3–6 месяцев без какого‑либо лечения и 6–12 месяцев при использовании системной химиотерапии. Доставка соответствующих химиотерапевтических препаратов напрямую в брюшную полость повышает эффективность лечения без тяжелых системных побочных эффектов. Сегодня в мире применяют разнообразные формы внутрибрюшной химиотерапии РЖ. Цель: Оценить эффективность гипертермической внутрибрюшной химиотерапии (HIPEC) и аэрозольной внутрибрюшной химиотерапии под давлением (PIPAC) в лечении ПМ РЖ. Задачи: Провести обзор актуальных отечественных и зарубежных публикаций, посвященных HIPEC и PIPAC, сравнить их эффективность. Материалы и методы: Были изучены и проанализированы статьи в базах данных PubMed, Scopus, Web of Science по ключевым запросам: «рак желудка», «канцероматоз», «перитонеальные метастазы», “HIPEC”, “PIPAC”. Выводы: Наилучшие результаты были достигнуты при использовании PIPAC в качестве предоперационной химиотерапии с последующим проведением ЦРХ в сочетании с HIPEC. Обе процедуры являются перспективными и требуют дальнейшего изучения с проведением многоцентровых рандомизированных проспективных исследований для оценки их лечебного потенциала.

Еще

Рак желудка, канцероматоз, перитонеальные метастазы, HIPEC, PIPAC

Короткий адрес: https://sciup.org/140304591

IDR: 140304591   |   DOI: 10.18027/2224-5057-2023-13-3-37-45

Список литературы HIPEC и PIPAC при раке желудка: методика и сравнение эффективности. Обзор литературы

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021 ; 71 (3) : 209-249. https://doi.org/10.3322/caac.21660.
  • Li Y, Feng A, Zheng S, Chen C, Lyu J. Recent Estimates and Predictions of 5-Year Survival in Patients with Gastric Cancer: A Model-Based Period Analysis. Cancer Control. 2022 Jan-Dec ; 29 : 10732748221099227. https://doi.org/10.1177/10732748221099227. PMID : 35499497.
  • Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res 1996 ; 82 : 53-63. CROSSREF. https://doi.org/10.1007/978-1-4613-1247-5_4.
  • Yonemura, Y., Canbay, E., Li, Y., Coccolini, F., Glehen, O., Sugarbaker, P. H., … Mahtem, H. (2016). A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. European Journal of Surgical Oncology (EJSO), 42 (8), 1123-1131. https://doi.org/10.1016/j.ejso.2016.03.016.
  • Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000 ; 88 : 358-363. https://doi.org/10.1002/(sici)1097-0142(20000115)88 : 2<358 :: aid-cncr16-3.0. co ; 2-o.
  • Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989 ; 63 : 364-367. https://doi.org/10.1002 / 1097-0142 (19890115) 63 : 2<364 :: aid-cncr2820630228-3.0. co ; 2-v.
  • Shirao K, Boku N, Yamada Y, Yamaguchi K, https://doi.org/T, Goto M, et al. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J ClinOncol 2013 ; 43 : 972-980. https://doi.org/10.1093/jjco/hyt114.
  • Oh SY, Kwon HC, Lee S, Lee DM, Yoo HS, Kim SH, et al. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J ClinOncol 2007 ; 37 : 930-935. https://doi.org/10.1093/jjco/hym131. PMID : 18211984.
  • Yamao, T. ; Shimada, Y. ; Shirao, K. ; Ohtsu, A. ; Ikeda, N. ; Hyodo, I. ; Saito, H. ; Iwase, H. ; Tamura, T. ; Yamamoto, S. ; et al. Phase II Study of Sequential Methotrexate and 5-Fluorouracil Chemotherapy against Peritoneally Disseminated Gastric Cancer with Malignant Ascites: A Report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn.J. Clin. Oncol. 2004, 34, 316-322. [Google Scholar] [CrossRef] [Green Version].
  • Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978 ; 62 : 1-11.
  • Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988 ; 61 (2) : 232e7. https://doi.org/10.1002/1097-0142(19880115)61 : 2<232 :: aid-cncr2820610205-3.0. co ; 2-u.
  • Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2016 Jan 21 ; 22 (3) : 1114-30. https://doi.org/10.3748/wjg.v22.i3.1114. PMID : 26811651 ; PMCID : PMC4716024.
  • Wu Y, Zheng X, Sun C, Wang S, Ding S, Wu M, Zhang J, Wang B, Xue L, Yang L, Tian Y, Xie Y. Hyperthermicintraperitoneal chemotherapy for patients with gastric cancer based on laboratory tests is safe: a single Chinese center analysis. BMC Surg. 2022 Sep 18 ; 22 (1) : 342. https://doi.org/10.1186/s12893-022-01795-6. PMID : 36115993 ; PMCID : PMC9482732.
  • Prabhu A, Mishra D, Brandl A and Yonemura Y (2022) Gastric Cancer With Peritoneal Metastasis-A Comprehensive Review of Current Intraperitoneal Treatment Modalities. Front. Oncol. 12 : 864647. https://doi.org/10.3389/fonc.2022.864647.
  • Filis P, Kanellopoulou A, Gogadis A, Filis N, Kamposioras K, Kapoulitsa F, Mauri D. Hyperthermicintraperitoneal chemotherapy for management of gastrointestinal and biliary tract malignancies: a systematic review and meta-analysis of randomized trials. Ann Gastroenterol. 2023 Jan-Feb ; 36 (1) : 87-96. https://doi.org/10.20524/aog.2023.0758. Epub 2022 Nov 15. PMID : 36593815 ; PMCID : PMC9756031.
  • Sun BJ, Lee B. Review of Regional Therapies for Gastric Cancer with Peritoneal Metastases. Cancers (Basel). 2022 Jan 23 ; 14 (3) : 570. https://doi.org/10.3390/cancers14030570. PMID : 35158837 ; PMCID : PMC8833629.
  • Gronau F, Feldbruegge L, Oberwittler F, Gonzalez-Moreno S, Villeneuve L, Eveno C, Glehen O, Kusamura S, Rau B. HIPEC in Peritoneal Metastasis of Gastric Origin: A Systematic Review of Regimens and Techniques. J Clin Med. 2022 Mar 7 ; 11 (5) : 1456. https://doi.org/10.3390/jcm11051456. PMID : 35268546 ; PMCID : PMC8911234.
  • González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermicintraperitoneal chemotherapy: Rationale and technique. World J GastrointestOncol. 2010 Feb 15 ; 2 (2) : 68-75. https://doi.org/10.4251/wjgo.v2.i2.68. PMID : 21160924 ; PMCID : PMC2999165.
  • Halkia E, Tsochrinis A, Vassiliadou DT, Pavlakou A, Vaxevanidou A, Datsis A, Efstathiou E, Spiliotis J. Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J SurgOncol. 2015 ; 2015 : 610597. https://doi.org/10.1155/2015/610597. Epub 2015 Feb 15. PMID : 25785194 ; PMCID : PMC4345051.
  • Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2016 Jan 21 ; 22 (3) : 1114-30. https://doi.org/10.3748/wjg.v22.i3.1114. PMID : 26811651 ; PMCID : PMC4716024.
  • Sun J, Song Y, Wang Z, Gao P, Chen X, Xu Y, Liang J, Xu H. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012 ; 12 : 526. https://doi.org/10.1186/1471-2407-12-526.
  • Mi DH, Li Z, Yang KH, Cao N, Lethaby A, Tian JH, Santesso N, Ma B, Chen YL, Liu YL. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hyperthermia. 2013 ; 29 : 156-167. https://doi.org/10.3109/02656736.2013.768359.
  • Markovich V.A., Tuzikov S.A., Rodionov E.O., Popova N.O., Tsyganov M.M., Miller S.V., Podolko D.V., Tsydenova I.A., Ibragimova M.K., Litviakov N.V. Combined modality treatment of patients with stage IV gastric cancer with peritoneal carcinomatosis. Siberian Journal of Oncology. 2023 ; 22 (1) : 24-34 .- https://doi.org/10.21294/1814-4861-2023-22-1-24-34.
  • Neuwirth MG, Alexander HR, Karakousis GC. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. https://doi.org/10.3978/j.issn.2078-6891.2015.106. PMID : 26941981 ; PMCID : PMC4754315.
  • Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann SurgOncol. 2011 Jun ; 18 (6) : 1575-81. https://doi.org/10.1245/s10434-011-1631-5. Epub 2011 Mar 23. PMID : 21431408 ; PMCID : PMC3087875.
  • Prabhu A, Mishra D, Brandl A and Yonemura Y (2022) Gastric Cancer With Peritoneal Metastasis-A Comprehensive Review of Current Intraperitoneal Treatment Modalities. Front. Oncol. 12 : 864647. https://doi.org/10.3389/fonc.2022.864647.
  • Bonnot P-E, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive Surgery With or Without HyperthermicIntraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP Study): A Propensity Score Analysis. J ClinOncol (2019) 37 (23) : 2028-40. https://doi.org/10.1200/jco.18.01688.
  • Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010 ; 17 : 2370-7. https://doi.org/10.1245/s10434-010-1039-7.
  • Chia CS, You B, Decullier E, et al. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and HyperthermicIntraperitoneal Chemotherapy: Is Cure a Possibility? Ann SurgOncol 2016 ; 23 : 1971-9. https://doi.org/10.1245/s10434-015-5081-3. Epub 2016 Jan 11. PMID : 26753751.
  • Garg, P. K. ; Jara, M. ; Alberto, M. ; Rau, B. The role of Pressurized IntraPeritoneal Aerosol Chemotherapy in the management of gastric cancer: A systematic review. Pleura Peritoneum, 2019. https://doi.org/10.1515/pp-2018-0127.
  • Van Cutsem, E. ; Cervantes, A. ; Adam, R. ; Sobrero, A. ; Van Krieken, J. H. ; Aderka, D. ; Aranda Aguilar, E. ; Bardelli, A. ; Benson, A. ; Bodoky, G. ; et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol., 2016. https://doi.org/10.1093/annonc/mdw235.
  • M. Hubner, F. Grass, H. Teixeira-Farinha, B. Pache, P. Mathevet, N. Demartines. Pressurized IntraPeritoneal Aerosol Chemotherapy- Practical aspects. European Journal of Surgery Oncology, 2017. https://doi.org/10.1016/j.ejso.2017.03.019. Epub 2017 Apr 8. PMID : 28431896.
  • Solass, W. ; Kerb, R. ; Mürdter, T. ; Giger-Pabst, U. ; Strumberg, D. ; Tempfer, C. ; Zieren, J. ; Schwab, M. ; Reymond, M.A. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy. Ann. Surg. Oncol. 2014. https://doi.org/10.1245/s10434-013-3213-1.
  • De Simone, M. ; Vaira, M. ; Argenziano, M. ; Berchialla, P. ; Pisacane, A. ; Cinquegrana, A. ; Cavalli, R. ; Borsano, A. ; Robella, M. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial. Biomedicines, 2020. https://doi.org/: 10.3390 / biomedicines8050102.
  • Alyami, Mohammad & Bonnot, Pierre-Emmanuel & Mercier, Frederic & Laplace, Nathalie & Villeneuve, Laurent & Passot, Guillaume & Bakrin, Naoual & Kepenekian, Vahan & Glehen, Olivier. (2020). Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. European Journal of Surgical Oncology. 47. 10.1016 / j. ejso. 2020.05.021.
  • Solass, W. ; Kerb, R. ; Mürdter, T. ; Giger-Pabst, U. ; Strumberg, D. ; Tempfer, C. ; Zieren, J. ; Schwab, M. ; Reymond, M.A. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy. Ann. Surg. Oncol. 2014. doi10.1245/s10434-013-3213-1.
  • Reymond MA, Solass W. PIPAC: Pressurized Intraperitoneal aerosol chemotherapy - cancer under pressure. Walter de Gruyter GmbH & Co KG ; 2014. https://doi.org/10.1007/s11605-015-2995-9.
  • Khomyakov V.M., Ryabov A.B., Kolobaev I.V., Bolotina L.V., Utkina A.B., Sobolev D.D., Kuznetsova O.S., Kaprin A.D. Pressurized intraperitoneal aerosol chemotherapy combined with system chemotherapy - a new approach to treatment of gastric cancer patients with peritonal carcinomatomosis. Siberian Journal of Oncology. 2020 ; 19 (4) : 49-58 .- https://doi.org/10.21294/1814-4861-2020-19-4-49-58.
  • Solass, W. ; Kerb, R. ; Murdter, T. ; Giger-Pabst, U. ; Strumberg, D. ; Tempfer, C. ; Zieren, J. ; Schwab, M. ; Reymond, M.A. Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy. Ann SurgOncol (2014) 21 : 553-559, doi10.1245/s10434-013-3213-1.
  • Weinreich, J. ; Struller, F. ; Sautkin, I. ; Giuashvili, S. ; Reymond, M. ; Konigsrainer, A. ; Schott, T. Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: Comparison of an experimental duplex drug to standard drug regimens in vitro. Investig. New Drugs 2018. https://doi.org/10.1007/s10637-018-0641-6.
  • Leebmann, H., &Piso, P. (2018). PIPAC und HIPEC - konkurrierendeoderergänzendeTherapieverfahrenbeiperitonealenMetastasen. Der Chirurg. https://doi.org/10.1007/s00104-018-0666-6.
  • Oyais, A., Solass, W., Zieren, J., Reymond, M., & Giger-Pabst, U. (2014). Arbeitssicherheitsaspekte der intraperitonealenDruck-Aerosol-Chemotherapie (PIPAC): Bestätigung der Unbedenklichkeit. ZentralblattFürChirurgie - ZeitschriftFürAllgemeine, Viszeral-, Thorax- Und Gefäßchirurgie, 141 (04), 421-424. https://doi.org/10.1055/s-0033-1350909.
  • Hübner, M., Teixeira Farinha, H., Grass, F., Wolfer, A., Mathevet, P., Hahnloser, D., &Demartines, N. (2017). Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study. Gastroenterology Research and Practice, 2017, 1-7. https://doi.org/10.1155/2017/6852749.
  • Axel Davigo, Guillaume Passot, Olivia Vassal, Muriel Bost, Clément Tavernier, EvelyneDecullier, NaoualBakrin, Mohammad Alyami, Jeanne-Marie Bonnet, Vanessa Louzier, ChristianPaquet, Bernard Allaouchiche, Olivier Glehen&VahanKepenekian (2020) PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model, International Journal of Hyperthermia, 37 : 1, 144-150, https://doi.org/10.1080/02656736.2019.1704891.
  • UrsGiger-Pabst, MD, PetruBucur, MD, PhD, Se´bastien Roger, PhD, Thomas Albert Falkenstein, MD, Nicolas Tabchouri, MD, Alain Le Pape, PhD, Ste´phanieLerondel, PhD, Ce´dricDemtro¨der, MD, EphremSalame´, MD, PhD, and Mehdi Ouaissi, MD, PhD. Comparison of Tissue and Blood Concentrations of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann SurgOncol, 2019 https://doi.org/doi.org10.1245s10434-019-07695-z.
  • Li, Zhenyue, Wong, Louis Choon Kit, Sultana, Rehena, Lim, Hui Jun, Tan, Joey Wee-Shan, Tan, QiuXuan, Wong, Jolene Si Min, Chia, ClaramaeShulyn and Ong, Chin-Ann Johnny. “A systematic review on quality of life (QoL) of patients with peritoneal metastasis (PM) who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC) ” Pleura and Peritoneum, vol. 7, no. 2, 2022, pp. 39-49. https://doi.org/10.1515/pp-2021-0154.
  • Girshally, R. ; Demtröder, C. ; Albayrak, N. ; Zieren, J. ; Tempfer, C. ; Reymond, M.A. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J. Surg. Oncol. 2016, 14, 253.
  • . Alyami, M. ; Bonnor, P. E. ; Mercier, F. ; Laplace, N. ; Villeneuve, L. ; Passot, G. ; Bakrin, N. ; Kepenekian, V. ; Glehen, O. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur.J. Surg. Oncol. EJSO 2020, 47, 123-127.
  • Alyami M, Bonnot PE, Mercier F, Laplace N, Villeneuve L, Passot G, et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Unresectable Peritoneal Metastasis From Gastric Cancer. Eur J SurgOncol (2021) 47 (1) : 123-7. https://doi.org/10.1016/j.ejso.2020.05.021.
  • Bonnot PE, Rabel T, Lintis A, Laplace N, Bakrin N, Kepenekian V, et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated to Systemic Chemotherapy for Gastric Cancer With Diffuse Peritoneal Metastases in a Palliative Setting. J ClinOncol (2020) 38, Issue 15 suppl. https://doi.org/10.1200/JCO.2020.38.15_suppl. e16538.
  • Facchiano, E., Risio, D., Kianmanesh, R., & Msika, S. (2012). Laparoscopic Hyperthermic Intraperitoneal Chemotherapy: Indications, Aims, and Results: A Systematic Review of the Literature. Annals of Surgical Oncology, 19 (9), 2946-2950. https://doi.org/10.1245/s10434-012-2360-0.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp